Evidence map›Paper›PMID 41098832›Full record

ArticleFrontiers in pharmacology2025

Antimicrobial activity of β-lactam antibiotics against pneumococcal isolates causing pneumococcal disease in adults immediately before and after the COVID-19 pandemic in Spain (2019-2020).

Mirella Llamosí, Covadonga Pérez-García, Aída Úbeda, Erick J Vidal-Alcántara, Inés Pareja-Cerbán, Elena Gómez-Rubio, Pilar Coronel, Juan Carlos Sanz, Mirian Domenech, Julio Sempere and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Antibacterial and Antibiofilm Activity ofJournal of fungi (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mirella Llamosí *Spanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Covadonga Pérez-García *Spanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Aída ÚbedaSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Erick J Vidal-AlcántaraSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Inés Pareja-CerbánSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Elena Gómez-RubioScientific Department, Meiji Pharma Spain, Alcala de Henares, Spain.
Pilar CoronelScientific Department, Meiji Pharma Spain, Alcala de Henares, Spain.
Juan Carlos SanzRegional Public Health Laboratory, Comunidad de Madrid, Madrid, Spain.
Mirian DomenechSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Julio SempereSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Jose YusteSpanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This study assessed the activity of β-lactam antibiotics against 1,018 clinical isolates of Results: Cefditoren showed the lowest MIC Conclusion: Despite the overall increase in resistance, cefditoren and cefotaxime retained favorable

Indexed as

AMRPCV20PCV21serotype 11Aserotype 14serotype 19Aserotype 24Fserotype 9V

Identifiers

PMID41098832
PMCPMC12518386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.